

Medical Coverage Policy | Optical Diagnostic Devices for Evaluating Skin Lesions Suspected of Malignancy



EFFECTIVE DATE: 06|01|2009
POLICY LAST UPDATED: 09|06|2016

OVERVIEW

There is interest in noninvasive devices that will improve the diagnosis of malignant skin lesions. One technique is dermatoscopy (dermoscopy, epiluminescence microscopy, in vivo cutaneous microscopy), which enables the clinician to perform direct microscopic examination of diagnostic features in pigmented skin lesions. Another approach is use of computer-based light imaging systems. These techniques have the potential to improve diagnostic accuracy for suspicious skin lesions and may increase the detection rate of malignant skin lesions and/or reduce the rate of unnecessary biopsies.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Dermatoscopy, using either direct inspection, digitization of images, or computer-assisted analysis, is considered not medically necessary as a technique to evaluate or serially monitor pigmented skin lesions due to a lack of peer-reviewed scientific literature proving the efficacy of the service.

Computer-based optical imaging devices, e.g., multispectral digital skin lesion analysis, are considered not medically necessary as a technique to evaluate or serially monitor pigmented skin lesions due to a lack of peer-reviewed scientific literature proving the efficacy of the service.

Dermatoscopy and computer-based optical imaging devices are considered not medically necessary for defining peripheral margins of skin lesions suspected of malignancy prior to surgical excision due to a lack of peer-reviewed scientific literature proving the efficacy of the service.

Note: Limited photography for documentation is considered part of record keeping and not separately reimbursed.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for limitations of benefits/coverage when services are not medically necessary.

BACKGROUND

Dermatoscopy, also known as dermoscopy, describes a family of noninvasive techniques that allow in vivo microscopic examination of skin lesions and is intended to help distinguish between benign and malignant pigmented skin lesions. The technique involves application of immersion oil to the skin, which eliminates light reflection from the skin surface and renders the stratum corneum transparent. Using a magnifying lens, the structures of the epidermis and epidermal-dermal junction can then be visualized. A handheld or stereomicroscope may be used for direct visual examination. Digitization of images, typically after initial

visual assessment, permits storage and facilitates their retrieval, is often used for comparison purposes if a lesion is being followed over time.

A variety of dermatoscopic features have been identified that are suggestive of malignancy, including pseudopods, radial streaming, the pattern of the pigment network, and black dots. These features in combination with other standard assessment criteria of pigmented lesions, such as asymmetry, borders, and color, have been organized into algorithms to enhance the differential diagnosis of pigmented skin lesions. Dermatoscopic images may be assessed by direct visual examination or by review of standard or digitized photographs. Digitization of images, either surface or dermatoscopic images, may permit qualitative image enhancement for better visual perception and discrimination of certain features, or actual computer-assisted diagnosis.

Interpretation of dermatoscopy findings have evolved over time. Initially, lesions were evaluated using pattern analysis. More recently several algorithms were developed, including the asymmetry, border, color and dermatoscopic structures (ABCD) rule of dermatoscopy, the 3-point and 7-point checklists of dermatoscopy by Argenziano, the Menzies method, and the CASH algorithm. There remains a lack of consensus in the literature regarding the optimal dermatoscopic criteria for malignancy.

Dermatoscopy is also proposed in the serial assessment of lesions over time and for defining peripheral margins prior to surgical excision of skin tumors.

Dermatoscopic devices cleared by the U.S. Food and Drug Administration (FDA) include:

- Episcopes™ (Welch Allyn, Inc., Skaneateles Falls, NY) approved in 1995; intended use is to illuminate body surfaces and cavities during medical examination.
- Nevoscope™ (TRANSLITE, Sugar Land, TX) approved in 1996; intended use is to view skin lesions by either illumination or transillumination.
- Dermascope™ (American Diagnostic Corp., Hauppauge, NY) approved in 1999; intended use is to enlarge images for medical purposes.
- MoleMax™ (Derma Instruments, Austria) approved in 1999; intended use is to enlarge images for medical purposes.

Recent meta-analyses found that overall, the diagnostic accuracy of dermatoscopy was higher than clinical assessment/naked eye examination. However, most studies are retrospective, reported on the performance of clinicians who have extensive experience with dermatoscopic imaging, and were conducted outside of the United States.

The evidence for dermatoscopy in patients who have lesions suspicious of melanoma is limited. The literature suggests that dermatoscopy is more accurate than naked eye examination when used in the expert clinical setting. The available evidence from prospective randomized controlled trials (RCTs) and other studies suggests that dermatoscopy used by specialists may lead to a decrease in the number of benign lesions excised and, when used by primary care physicians, may lead to fewer benign lesions being referred to specialists. The number of studies on the impact of dermatoscopy on patient management and clinical outcomes remains limited. The evidence is insufficient to determine the effects of the technology on health outcomes, and the service is considered not medically necessary.

The evidence for dermatoscopy in patients who have pigmented lesions being monitored for suspicious changes does not clearly indicate that dermatoscopy results in better patient management decisions. The evidence is insufficient to determine the effects of the technology on health outcomes. Therefore, the service is considered not medically necessary.

Computer-Based Optical Diagnostic Devices

An FDA-approved multispectral digital skin lesion analysis (MSDSL) device uses a handheld scanner to shine visible light on the suspicious lesion. The light is of 10 wavelengths, varying from blue (430 nm) and near infrared (950 nm). The light can penetrate up to 2.5 mm under the surface of the skin. The data acquired by the scanner are analyzed by a data processor; the characteristics of each lesion are evaluated using proprietary computer algorithms. Lesions are classified as positive (i.e., high degree of morphologic disorganization) or negative (i.e., low degree of morphologic disorganization) according to the algorithms. Positive lesions are recommended for biopsy. For negative lesions, other clinical factors are considered in the decision of whether or not to refer to biopsy. The FDA-approved system noted below is intended only for suspicious pigmented lesions on intact skin and for use only by trained dermatologists.

One computer-based optical imaging device has been cleared by FDA. MelaFind® (MelaSciences Inc. Irvington, NY) was approved in November 2011. Its intended use is to evaluate pigmented lesions with clinical or histologic characteristics suggestive of melanoma. It is not intended for lesions with a diagnosis of melanoma or likely melanoma. MelaFind is intended for use only by physicians trained in the clinical diagnosis and management of skin cancer (i.e., dermatologists) and only those who have additionally successfully completed training on the MelaFind device.

The evidence for computer-based optical diagnostic devices in patients who have lesions suspicious of melanoma is insufficient to determine the effects of the technology on health outcomes. The evidence for computer-based optical diagnostic device in patients who have pigmented lesions being monitored for suspicious changes includes no published studies. The evidence is insufficient to determine the effects of the technology on health outcomes. Therefore, the service is considered not medically necessary.

CODING

BlueCHiP for Medicare and Commercial Products

The following code, when performed with or without dermatoscopy, is considered **not medically necessary**:

96904

0400T

0401T

Whole body photography represents one component of dermatoscopy. CPT code 96904 may also be submitted to describe whole body photography without dermatoscopy.

RELATED POLICIES

CPT Category III Codes

PUBLISHED

Provider Update, November 2016

Provider Update, January 2016

Provider Update, September 2014

Provider Update, September 2013

Provider Update, May 2012

Provider Update, May 2011

Provider Update, May 2010

REFERENCES

1. Kardynal A, Olszewska M. Modern non-invasive diagnostic techniques in the detection of early cutaneous melanoma. *J Dermatol Case Rep.* Mar 31 2014;8(1):1-8. PMID 24748903
2. Vestergaard ME, Macaskill P, Holt PE et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. *Br J Dermatol* 2008; 159(3):669-676. PMID

3. Rajpara SM, Botello AP, Townend J et al. Systematic review of dermoscopy and digital dermoscopy/artificial intelligence for the diagnosis of melanoma. *Br J Dermatol* 2009; 161(3):591-604. PMID
4. Unlu E, Akay BN, Erdem C. Comparison of dermatoscopic diagnostic algorithms based on calculation: The ABCD rule of dermoscopy, the seven-point checklist, the three-point checklist and the CASH algorithm in dermatoscopic evaluation of melanocytic lesions. *J Dermatol*. Jul 2014;41(7):598-603. PMID 24807635
5. De Giorgi V, Grazzini M, Rossari S, et al. Adding dermoscopy to naked eye examination of equivocal melanocytic skin lesions: effect on intention to excise by general dermatologists. *Clin Exp Dermatol*. 2011;36(3):255-259. PMID
6. Rosendahl C, Tschandl P, Cameron A, et al. Diagnostic accuracy of dermoscopy for melanocytic and nonmelanocytic pigmented lesions. *J Am Acad Dermatol*. 2011;64(6):1068-1073. PMID
7. Annessi G, Bono R, Sampogna F et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. *J Am Acad Dermatol* 2007; 56(5):759-767. PMID
8. Carli P, de Giorgi V, Chiarugi A, et al. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. *J Am Acad Dermatol*. May 2004;50(5):683-689. PMID 15097950
9. Argenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. *J Clin Oncol*. Apr 20 2006;24(12):1877-1882. PMID 16622262

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

